Compass Therapeutics, Inc.

Compass Therapeutics, Inc. (Nasdaq Capital Market: CMPX) is a clinical-stage biopharmaceutical company focused on developing proprietary antibody-based therapeutics for oncology applications. The company's website is located at https://investors.compasstherapeutics.com.

The company's scientific strategy centers on the relationship between angiogenesis, the immune system, and tumor growth. Compass Therapeutics develops product candidates designed to target multiple critical biological pathways required for effective anti-tumor responses, including modulation of the microvasculature through angiogenesis-targeted agents, induction of potent immune responses via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance.

The company maintains a pipeline of four clinical-stage product candidates. Tovecimig, the lead candidate, is a bispecific antibody targeting Delta-like ligand 4 and vascular endothelial growth factor A, currently undergoing a randomized Phase 2/3 trial in combination with paclitaxel for biliary tract cancer patients. CTX-471 is an agonistic antibody targeting CD137, a co-stimulatory receptor on immune cells, with Phase 1 data demonstrating activity in post-checkpoint inhibitor patient populations. CTX-8371 is a bispecific antibody targeting both PD-1 and PD-L1, currently in Phase 1 clinical trials with demonstrated deep responses across multiple tumor types. CTX-10726 is a bispecific antibody targeting PD-1 and VEGF-A that recently received FDA clearance for its investigational new drug application.

Compass Therapeutics employs proprietary discovery platforms, including its StitchMabs technology, to generate a broad pipeline of product candidates. The company has licensed exclusive global rights to tovecimig outside South Korea from ABL Bio, Inc., with South Korean rights held by Handok Pharmaceuticals and China rights out-licensed to Elpiscience Biopharmaceuticals. The company also maintains collaboration agreements with Adimab for antibody development and commercialization.

As a clinical-stage company with no approved products or product revenues, Compass Therapeutics has not yet achieved profitability and expects to continue incurring significant losses as it advances its pipeline through clinical development and regulatory approval processes.